Mito-LND

Research use only, not for human use.

Mito-LND is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation.

Mito-LND is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation.

Mito-LND blocks lung cancer growth, migration, and invasion. Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 values of 0.74 μM and 0.69?μM, respectively.Mito-LND inhibits mitochondrial complex I and II activities with IC50 values of 1.2 μM and 2.4?μM, respectively in H2030BrM3 cells. Mito-LND (1?μM) increases ROS generation in H2030BrM3 lung cancer cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells.Mito-LND (2?μM) decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling.

Mito-LND (7.5?μmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) treatment markedly enhanced potency against both lung cancer progression and metastasis. Mito-LND also decreases the rate of growth of A549 tumor xenografts.Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells. Animal Model:Athymic nude mice (5 weeks) injected with H2030BrM3 cells Dosage:7.5?μmol/kg Administration:Oral gavage; 5 days per week; for 3 consecutive weeks Result:Significantly decreased tumor progression.

Mito-Loidamine

Others

Other Targets

oxidative phosphorylation (OXPHOS)

——

——

2361564-49-8

801.62

C43H45BrCl2N3OP

>98% (HPLC)

DMSO:45mg/ml(56.14mM; need ultrasonic)

O=C(NCCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C4=NN(CC5=CC=C(Cl)C=C5Cl)C6=C4C=CC=C6.[Br-]

——

(-20℃)

With Ice Pack

≥ 2 years